期刊文献+

TSP50在肺腺癌中的表达及意义 被引量:1

The expression and significance of TSP in adenocarcinoma of lung
下载PDF
导出
摘要 目的探讨睾丸特异性蛋白酶50(testes-specific protease 50,TSP50)在肺腺癌组织中的表达及其临床意义。方法应用免疫组织化学方法检测TSP50蛋白在72例肺腺癌及癌旁组织标本中的表达情况,分析其与各临床病理特征的关系。结果 TSP50在肺腺癌组织中阳性表达率为73.6%,显著高于癌旁组织(P<0.01);TSP50蛋白表达与肿瘤的淋巴结转移状态、临床分期存在明显相关性(P=0.009,P=0.022),而与肺腺癌患者的性别、年龄、肿瘤大小、吸烟史、组织学类型无明显相关性(P>0.05)。结论 TSP50在肺腺癌中高表达,与肺腺淋巴结转移及临床分期显著正相关,有望成为新的肺腺癌的治疗靶点。
作者 胡幸 邓星辉 何凯宁 HU Xing;DENG Xing-hui;HE Kai-ning
出处 《广东医学》 CAS 2019年第14期2083-2086,共4页 Guangdong Medical Journal
  • 相关文献

参考文献3

二级参考文献62

  • 1Jemal A,Siegel R,Ward E,et al. Cancer statistics,2007 [J]. CA Cancer J Clin, 2007,57(1) :43-66.
  • 2Vijayalakshmi R,Krishnamurthy A. Targetable "driver" mutations in non small cell lung cancer [J]. Indian J Surg Oncol, 2011,2(3) : 178-88.
  • 3Pao W,Miller V,Zakowski M,et al. EGF receptor gene mutations are common in lung cancers from "never smok- ers" and are associated with sensitivity of tumors to gefi- tinib and erlotinib [J]. Proc Natl Acad Sci USA,2004,101 (36): 13306-11.
  • 4Yang JC-H,Schuler MH,Yamamoto N,et al. LUX-Lung 3:A randomized,open-label,phase Ⅲ study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung har- boring EGFR-activating mutations[J]. J Clin Oncol,2012, (suppl) : abstr LBA7500.
  • 5Wu YL,Zhou CC,Hu CP,et al. LUX-Lung 6:A random- ized,open-label,phase Ⅲ study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients(pts) with EGFR mutation-positive (EGFR M+) ad- vanced adenocarcinoma of the lung [J]. J Clin Oncol, 2013, (suppl) : abstr 8016.
  • 6Engelman JA,Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor,is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].Cancer Res, 2007,67 (24) : 11924- 11932.
  • 7Goldberg Z,Kris M,Janne PA,et al. Dacomitinib (PF- 00299804),an irreversible pan-HER tyrosine kinase in- hibitor (TKI),for first-line treatment of EGFR-mutant or HER2-mutant or-amplified lung cancers [J]. 2012,ESMO Abstract 12280.
  • 8Ramalingam SS,Blackhall F,Krzakowski M,et al. Ran- domized phase Ⅱ study of dacomitinib (PF-O0299804),an irreversible pan-human epidermal growth factor receptor inhibitor,versus erlotinib in patients with advanced non- small-cell lung cancer [J]. J Clin Oncol,2012,30(27): 3337-3344.
  • 9Mao C, Qiu LX, Liao RY,et al. KRAS mutations and resis- tance to EGFR-TKIs treatment in patients with non-small- cell lung cancer:a meta-analysis of 22 studies [J]. Lung Cancer, 2010,69(3) :272-278.
  • 10Janne PA,Shaw AT, Rodrigues PJ,et al. Efficacy and pa- tient(PT)-reported outcomes (PROS) with selumetinib (AZD6244,ARRY-142866;SEL) + docetaxel (DOG) in KRAS-mutant advanced randomized,phase Ⅱ trial [J]. 2012, ESMO Abstract 1233PD.

共引文献37

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部